Abstract

The invention is based on the detection of the involvement of the K63-specific deubiquitinase CYLD in the manifestation of autism spectrum disorder in a mouse model. The invention therefore provides methods for the diagnosis of such a disorder as well as methods for the development of new autism diagnostics. Further provided are means and methods for use in therapeutically modulating any manifestation of an autism spectrum disorder, or intellectual disability (ID), in a mammal or associated neuropsychiatric manifestations.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a method for determining the measure of the degree of an obstructive sleep apnea and/or its consequence by means of the following steps: defining a measure of the degree of an obstructive sleep apnea and/or its consequence, providing two EEG measurement signals of an electroencephalography at the electroencephalography points of an 10-20 international EEG system, dividing the EEG measurement signals into frequency bands, determining at least one cross-frequency modulation index using data from at least two different frequency bands, determining the measure of the degree of an obstructive sleep apnea and/or its consequences by means of the at least one cross-frequency modulation index. The invention further relates to a device for carrying out the method.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

Roller shutter rod, comprising a body with a head end and a foot end, wherein a hook is arranged at one of the two ends and a chamber for receiving the hook is formed at the other of the two ends a chamber is formed for receiving the hook, wherein the chamber is formed in two parts in such a way that it enables a hook to be received in two directions opposite to a centre plane of the roller shutter rod.

IPC Classes  ?

• E06B 9/15 - Roller shutters with closing members formed of slats or the like

Abstract

Many next-generation biomaterials will need the ability to not only promote healthy tissue integration but to simultaneously resist bacterial colonization and resulting biomaterials-associated infection. For this purpose, antimicrobial nanofibers of polycaprolactone (PCL) were fabricated by incorporating calcium peroxide. PCL nanofibers containing different ratios of calcium peroxide (1%, 5% and 10% (w/w)) with or without ascorbic acid were fabricated using an electrospinning technique. Antimicrobial evaluations confirmed the inhibitory properties of the nanofibers on the growth of E. coli and S. epidemidis because of a significant burst release of calcium peroxide from the nanofibers. Analysis of tissue cell response showed that despite an initial toxic effect over the first 24 h, after 4 days of culture, osteoblast viability and morphology were both healthy. These results demonstrate that oxygen-generating nanofibers can be designed and developed to provide a short-term peroxide-based antimicrobial response while still maintaining attractive tissue-integration properties.

IPC Classes  ?

• A61K 33/40 - Peroxides
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to methods for detecting the presence and/or predicting the severity or stage of chronic liver fibrosis in an individual, comprising the analysis of the expression levels of at least two markers selected from the group consisting of matricellular fibrosis marker thrombospondin-2 (TSP2), insulin like growth factor binding protein 7 (IGFBP7), growth differentiation factor 15 (GDF-15), macrophage marker CD163, matricellular fibrosis markers thrombospondin-4 (TSP4), ADAMTS9, ADAPT, ADAPTI, ADAPT-2, FIB-4 or Pro-C3 in a biological sample obtained from said individual. The invention also relates to methods for predicting the efficacy of a treatment of a chronic liver fibrosis in an individual, comprising the analysis of said at least two markers. The invention furthermore relates to diagnostic or therapeutic test systems, comprising reagents and material that allow the analysis of said at least two markers. The diagnostic or therapeutic test system according to the present invention are suitable for use in the diagnosis of chronic liver fibrosis in an individual. The invention further relates to a composition of said at least two markers for use in the treatment of chronic liver diseases by predicting the response to treatment with a candidate agent and/or monitoring the fibrogenesis of chronic liver fibrosis under such therapy, or with, e.g., nutritional or life style intervention. The invention also relates to methods of selecting or qualifying a pharmaceutically active candidate agent or a nutritional or life style intervention for inhibiting the progression or inducing the regression of a chronic fibrotic liver disease in a patient, and a candidate agent or intervention derived from said methods.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to novel tumor-associated antigens, which elicit a T-cell response independently from a presentation by MHC. PD-L1 was found to be a target of CD8-positive T-cell clones which could detect their target antigen on the surface of HLA I-negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Also provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells specifically reactive to the antigens of the invention in an MHC-independent manner.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/365 - Lactones
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a device (10) for retracting and extending a flexible and/or foldable material sheet (20), which comprises a holding element such as a winding shaft (12) and a drive (14). The material sheet (20) is able to be retracted and extended on the holding element, in particular wound and unwound around the holding element (12) or gathered and ungathered on the holding element. The drive (14) is designed to drive a translational movement of the device along a travel path. The device (10) is designed, as a result of the translational movement driven by the drive (14), to vary an extended portion of the material sheet (20) by retracting or extending the material sheet (20). The invention also relates to a system (100) for selectively covering a surface (210) with such a device (10) and to a building structure (200) which is equipped with such a system (100).

IPC Classes  ?

• E06B 9/66 - Operating, guiding or securing devices or arrangements for roll-type closuresSpring drumsTape drumsCounterweighting arrangements therefor with a roller situated at the bottom
• E04H 4/10 - Coverings of flexible material

Abstract

Disclosed herein is a method of and an apparatus for combined ion mobility and mass spectrometry analysis, the method comprising the following steps: introducing precursor ions (34) into a trap configured for trapping ions and for selectively ejecting trapped ions according to their m/z ratio, selectively ejecting precursor ions (34) having m/z values falling within at least one controllable ejection window from said trap (15), sequentially releasing precursor ions (34) from said IMS (16) according to their ion mobility, introducing said released precursor ions (34) into a mass filter (26) having a controllable mass window, fragmenting the precursor ions (34) transmitted through said mass filter (26) to generate fragment ions, and carrying out a mass spectrometry measurement on said fragment ions, wherein each fragment ion is associated with a mass window and an ion mobility (IM) range.

IPC Classes  ?

• G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

The invention relates to a movable solar cell device (10) having a flexible and/or foldable carrier substrate (12) and an arrangement of solar cells (14) disposed on the carrier substrate (12). The solar cell device (10) is movable by being rolled up or gathered up. The invention also relates to a building structure (110, 120) which has a light-permeable surface (130, 140) and a movable solar cell device (10) of this kind, which is disposed in front of or behind the light-permeable surface (130, 140). The invention also relates to a method for operating a movable solar cell device (10) of this kind.

IPC Classes  ?

• H02S 20/30 - Supporting structures being movable or adjustable, e.g. for angle adjustment
• H02S 30/20 - Collapsible or foldable PV modules
• H02S 20/22 - Supporting structures directly fixed to an immovable object specially adapted for buildings

Abstract

The present invention relates to hydrophilic (co)polymers having chemically reactively (covalently) bound anchor groups and/or crosslinker molecules that permit attachment to the parent substrate or linkage of these polymers to networks. The invention further relates to hydrogels and coatings, especially implant coatings, comprising the polymers of the invention, and to medical devices, such as implants, that have been coated with a coating of the invention.

IPC Classes  ?

• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08F 8/12 - Hydrolysis
• C09D 133/24 - Homopolymers or copolymers of amides or imides

Abstract

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The current disclosure provides methods and composition for treatment of autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome. Certain aspects of the disclosure are directed to methods for treatment of an autoimmune or inflammatory condition comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2/proline. Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2/proline and, in some cases, one or more additional anti-inflammatory agents.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to inhibitors, pharmaceutical compositions and methods for inhibiting the expression of Fos-related antigen-1 (Fra-1) or Fos-related antigen-2 (Fra-2) in fibrogenic tissue cells for use in the treatment or prevention of organ or tissue fibrosis. The inhibitor of the present invention is characterized in that it interferes with Fra-1 or Fra-2 expression, resulting in a reduction in the amount of Fra-1 or Fra-2 in said fibrogenic cells to levels found in non-fibrotic healthy cells or tissues.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

Novel inhibitors of the Tissue Factor-Protease Activated Receptor 2 (TF-PAR2) signaling pathway for use in the treatment or prevention of heart failure (HF). In-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (MI), comprise the steps of (i) determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-β1 in a biological sample collected from said subject, and (ii) comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-β1 are indicative for an increased risk of developing IHF or adverse remodeling following MI.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for detecting and/or predicting the severity and/or chronicity of a systemic pulmonary disease (SPD) in a patient, comprising determining the expression of at least two markers selected from the group consisting of macrophage marker CD163, matricellular fibrosis marker thrombospondin-2 (Tsp2), and (cardiovascular) inflammation/repair marker growth differentiation factor 15 (GDF-15) in a sample obtained from said patient, optionally with complementation by insulin like growth factor binding protein 7 (IGFBP7). The method is particularly useful in case of SPDs such as influenza infection, such as, for example, influenza A virus infection, interstitial lung disease (ILD, IPF), acute respiratory distress syndrome (ARDS), and coronavirus infection, such as, for example, COVID19 and long COVID19.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Rheum palmatumRheum palmatum) root extract and one or more additives selected from the group consisting of Acemannan and/or Glucomannan, or plant extracts containing said compounds for use in the prevention or treatment of oral or dental disorders or dysfunctions. Furthermore, the invention relates to a mouth rinse solution or dentifrice composition for use in oral or dental care.

IPC Classes  ?

• A61K 36/708 - Rheum (rhubarb)
• A61K 36/886 - Aloeaceae (Aloe family), e.g. aloe vera
• A61K 36/258 - Panax (ginseng)
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Abstract

A method for classifying a polysomnography recording into defined sleep stages. The method comprises essentially the following steps: classifying the sleep of a human being into a grid with different sleep stages, collecting a plurality of information on bodily functions over a predetermined period of time in the form of data, wherein collecting the plurality of information comprises at least one measuring and recording of brain electrical activity data over a predetermined period of time during sleep of a person, subdividing the collected data into time-dependent data blocks, selecting a predetermined number of data blocks from the data blocks, wherein said data blocks include data on the electrical activity of the brain, automatically evaluating the brain electrical activity data in each selected data block using a cross-frequency coupling method, and automatically assigning the evaluated data blocks to a sleep stage.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

The present invention relates to a method for determining a scale for the degree of obstructive sleep apnoea and/or the after-effect thereof using the following steps: - defining a scale for the degree of obstructive sleep apnoea and/or the after-effect thereof, - providing two EEG measurement signals from an electroencephalograph at the electroencephalograph points of an international 10-20 EEG system, - dividing the EEG measurement signals into frequency bands, - determining at least one cross frequency modulation index using data from at least two different frequency bands, - determining the scale for the degree of obstructive sleep apnoea and/or the after-effect thereof using the at least one cross frequency modulation index. The invention further relates to a device for performing the method.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

Autologous prevascularized breast tissue constructs created via 3D printing and methods for 3D printing autologous prevascularized breast tissue constructs. The method comprises steps of: (i) providing a triculture consisting of adipose mesenchymal stem cells, fibroblasts, and endothelial progenitor cells, (ii) mixing the triculture cells with a bioink composed of biopolymers, (iii) printing three-dimensional structures of the breast tissue construct using the triculture-added bioink from step (ii), where the cells of the triculture are pretreated with growth media before printing so that the endothelial progenitor cells differentiate into endothelial cells and the adipose mesenchymal stem cells differentiate into adipocytes. After 3D printing, the development of vascular-like structures is induced.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Abstract

The present invention relates to compositions and kits comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, and one or more inorganic peroxide (CaO2 ZnO2 and/or MgO2) for use in the prevention or treatment of wounds, and/or pathological conditions requiring wound healing, tissue regeneration and/or bone regeneration. The present invention is in particular suitable for the prevention or treatment of a gum disease.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 33/08 - OxidesHydroxides
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61Q 11/02 - Preparations for deodorising, bleaching or disinfecting dentures

Abstract

2222) for use in the prevention or treatment of wounds, and/or pathological conditions requiring wound healing, tissue regeneration and/or bone regeneration. The present invention is in particular suitable for the prevention or treatment of a gum disease.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 33/08 - OxidesHydroxides
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61Q 11/02 - Preparations for deodorising, bleaching or disinfecting dentures

Abstract

The present invention relates to method of detecting endocannabinoids from dried blood spots. The present invention further relates to a method for diagnosing and/or monitoring a disease or condition which is related to a change of the concentration of endocannabinoid(s) in the blood or plasma, which comprises the detection method. The present invention further relates to a method for control testing.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

The invention relates to a roller blind slat (1, 1a, 1b, 1c) comprising a body (8) having a head end (12) and a foot end (14), wherein a hook (2) is arranged at one of the two ends (12, 14) and a chamber (3) for receiving the hook (2) is formed at the other of the two ends (12, 14), wherein the chamber (3) is formed in two parts in such a way as to enable a hook (2) to be received in two opposite directions with respect to a central plane (22) of the roller blind slat (1, 1a, 1b, 1c).

IPC Classes  ?

• E06B 9/15 - Roller shutters with closing members formed of slats or the like
• E06B 9/58 - Guiding devices

Abstract

According to the disclosure, a method for reconstructing a brain network (205), comprises providing, in a memory of a computing device, an image of at least a section of a subject's brain (201); determining, in a processing unit of the computing device, a three-dimensional volume model (202) of the section of the subject's brain (201); segmenting, by the processing unit, the volume model (202) into a plurality of sub-volumes, each sub-volume corresponding to an anatomical subfield of the subject's brain (201) and having a volume value; for each of the sub-volumes, determining, by the processing unit, a modified volume for the sub-volume, wherein determining said modified volume comprises calculating said modified volume based on the volume value of the sub-volume and variables multiplied with constants, wherein the constants are constants determined for a population, comprising a plurality of individuals, to which the subject belongs; for each combination of two sub-volumes, determining, by the processing unit, a similarity between the sub-volumes, based on a comparison of the respective modified volume for each of the sub-volumes; and determining, by the processing unit, a brain network (205) for the section of the subject's brain (201). The brain network (205) comprises nodes (206), each node (206) representing one of the sub-volumes, and edges (207), each edge (207) connecting two nodes (206) and being indicative of the determined similarity between the sub-volumes. At least one of the steps from the group of storing the brain network (205) in the memory of the computing device, displaying the brain network (205) on a display unit of the computing device, and sending the brain network (205) to a remote computing device via a transmission unit of the computing device is performed. Further, a method for monitoring a brain network, a computing device, a computer program product and a computer-readable storage medium are provided.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The invention is based on the detection of the involvement of the K63-specific deubiquitinase CYLD in the manifestation of autism spectrum disorder in a mouse model. The invention therefore provides methods for the diagnosis of such a disorder as well as methods for the development of new autism diagnostics. Further provided are means and methods for use in therapeutically modulating any manifestation of an autism spectrum disorder, or intellectual disability (ID), in a mammal or associated neuropsychiatric manifestations.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to methods for detecting whether a subject suffers from an autoimmune disease, such as, for example, antiphospholipid syndrome (APS), by detecting antiphospholipid antibodies (aPL) in a sample using a novel target, the lysobisphosphatidic acid (LBPA) bound to the endothelial protein C receptor (EPCR) or an LBPA-binding fragment thereof. Furthermore, the present invention relates to methods for identifying an inhibitor of endothelial protein C receptor (EPCR) function in autoimmune disease, preferably without a side effect on EPCR regulatory function in coagulation, and a method for producing a pharmaceutical composition comprising the steps of identifying a potential inhibitor, and suitably formulating said potential inhibitor into a pharmaceutical composition. Moreover, the present invention relates to said inhibitor as identified or said pharmaceutical composition for use in the prevention and/or treatment of an autoimmune disease, such as, for example, an antiphospholipid syndrome, in a subject. Furthermore, the present invention relates to a method for treating and/or preventing an autoimmune disease, such as, for example, antiphospholipid syndrome, in a subject.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The current disclosure provides methods and composition for treatment of autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome. Certain aspects of the disclosure are directed to methods for treatment of an autoimmune or inflammatory condition comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2/proline. Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2/proline and, in some cases, one or more additional anti-inflammatory agents.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C07K 14/81 - Protease inhibitors
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The current disclosure provides methods and composition for treatment of autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome. Certain aspects of the disclosure are directed to methods for treatment of an autoimmune or inflammatory condition comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2/proline. Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2/proline and, in some cases, one or more additional anti-inflammatory agents.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C07K 14/81 - Protease inhibitors
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

Prooxidative chain-transfer agents for use in the treatment of a malignant tumour disease, or infectious disease. The prooxidative chain-transfer agents are selected from lipophilic thiols, lipophilic trithiocarbonates, lipophilic, aromatic dithioesters, and lipophilic, aromatic thiols. The compounds amplify the prooxidative activity at the target site and are therefore highly efficient and specific for their targets.

IPC Classes  ?

• A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
• A61P 35/00 - Antineoplastic agents
• A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols

Abstract

A device and method for determining the severity of sleep apnea using electroencephalography and electromyography. The device includes a headgear having a head part sized to cover the head of a patient, at least at the locations where the measuring points C3 and C4 of the electroencephalography are situated, and a chin part, and wherein the head part has two electrodes for sensing EEG-signals of the electroencephalography at the electroencephalography points C3 and C4, and the chin part has at least one electrode for sensing the EMG-signal of the electromyography in the chin.

IPC Classes  ?

• A61N 1/00 - ElectrotherapyCircuits therefor
• A61B 5/308 - Input circuits therefor specially adapted for particular uses for electrocardiography [ECG]
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Disclosed herein is a method of and an apparatus for combined ion mobility and mass spectrometry analysis, the method comprising the following steps: introducing precursor ions (34) into a trap configured for trapping ions and for selectively ejecting trapped ions according to their m/z ratio, selectively ejecting precursor ions (34) having m/z values falling within at least one controllable ejection window from said trap (15), sequentially releasing precursor ions (34) from said IMS (16) according to their ion mobility, introducing said released precursor ions (34) into a mass filter (26) having a controllable mass window, fragmenting the precursor ions (34) transmitted through said mass filter (26) to generate fragment ions, and carrying out a mass spectrometry measurement on said fragment ions, wherein each fragment ion is associated with a mass window and an ion mobility (IM) range.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry

Abstract

A finger motion rail, and a therapeutic device with a finger motion rail for carrying out a continuous, passive and/or actively assisted movement of a finger and/or thumb. A multi-joint hinge, arranged laterally alongside a finger and/or thumb, for flexion of a metacarpophalangeal joint. The multi-joint hinge is operatively connected via a first connection lever, at least one second connection lever and at least one connection joint, to a mechanism also arranged laterally alongside the respective finger and/or thumb, for flexion of a proximal interphalangeal joint and/or a distal interphalangeal joint. The finger motion rail and therapeutic device is configured as robust against the effect of compressive, tensile and torsional forces, with respect to a longitudinal axis of the finger motion rail, and it permits precise and interference-free execution of an anatomically natural, automated finger movement, for increased chance of successful therapy and the service life of the device.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

A length adjustment device for a finger motion rail of a therapeutic device, a finger motion rail having such a length adjustment device, a therapeutic device having such a finger motion rail, and a method for adjusting the length of a finger motion rail on a therapeutic device for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a hand. The length adjustment device and adjustment method having a finger motion rail that is automatically moved along an adjustment rail by a drive on a therapeutic device and allows the finger motion rail to be fixed on the adjustment rail and therefore on the therapeutic device at a desired position in order to then be able to carry out a continuous, passive and/or actively assisted movement of a finger and/or of a thumb of a hand in a stable position.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. Said compounds have been identified through methods of pharmacological screening on a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/415 - 1,2-Diazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4462 - Non-condensed piperidines, e.g. piperocaine only substituted in position 3
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

Modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. Embodiments of the invention further relate to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening, methods for the preparation of a modified NK-92 that is specific for a target antigen of a target cell in a subject, and to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors
• C07K 14/73 - CD4
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

A method for classifying or categorizing a polysomnography recording into defined sleep tags.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/087 - Measuring breath flow
• A61B 7/00 - Instruments for auscultation
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/369 - Electroencephalography [EEG]
• A61B 5/389 - Electromyography [EMG]
• A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
• A61B 5/024 - Measuring pulse rate or heart rate

Abstract

in-vitroin-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (Ml), comprising the steps of i. determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-β1 in a biological sample collected from said subject, ii. comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-β1 are indicative for an increased risk of developing IHF or adverse remodeling following Ml.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to novel inhibitors of the Tissue Factor-Protease Activated Receptor 2 (TF-PAR2) signaling pathway for use in the treatment or prevention of heart failure (HF). The invention furthermore relates to an in-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (Ml), comprising the steps of i. determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-ß1 in a biological sample collected from said subject, ii. comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-ß1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-ß1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-ß1 are indicative for an increased risk of developing IHF or adverse remodeling following Ml.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to a method for classifying a polysomnography recording into defined sleep stages, the method comprising essentially the following steps: - dividing the sleep of a person into a pattern with various sleep stages, - acquiring a multiplicity of items of information relating to bodily functions over a predefined period in the form of data, wherein the acquisition of the multiplicity of items of information comprises at least measuring and storing the electrical activity of the brain over a predefined period while a test person is sleeping, - subdividing the acquired data into time-dependent data blocks, - selecting a predefined number of data blocks from the data blocks, wherein these data blocks contain information relating to the electrical activity of the brain, - automatically evaluating the data relating to the electrical activity of the brain in each selected data block by means of a cross-frequency coupling method, - automatically assigning the evaluated data blocks to a sleep stage.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to a method for classifying a polysomnography recording into defined sleep stages, the method comprising essentially the following steps: - dividing the sleep of a person into a pattern with various sleep stages, - acquiring a multiplicity of items of information relating to bodily functions over a predefined period in the form of data, wherein the acquisition of the multiplicity of items of information comprises at least measuring and storing the electrical activity of the brain over a predefined period while a test person is sleeping, - subdividing the acquired data into time-dependent data blocks, - selecting a predefined number of data blocks from the data blocks, wherein these data blocks contain information relating to the electrical activity of the brain, - automatically evaluating the data relating to the electrical activity of the brain in each selected data block by means of a cross-frequency coupling method, - automatically assigning the evaluated data blocks to a sleep stage.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to methods for the 3D printing of autologous, prevascularized breast tissue constructs, said methods comprising the steps of: (i) providing a triculture, consisting of adipose mesenchymal stem cells, fibroblasts and endothelial progenitor cells, (ii) mixing the triculture cells with a bioink consisting of biopolymers, (iii) printing three-dimensional structures of the breast tissue construct using the bioink from step (ii), to which the triculture has been added, wherein the cells of the triculture are pretreated with growth media prior to the printing process so that the endothelial progenitor cells differentiate to form endothelial cells and the adipose mesenchymal stem cells differentiate to form adipocytes. After the 3D printing, the development of vascular-like structures is induced. The invention also relates to autologous, prevascularized breast tissue constructs produced by means of such a 3D printing method.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61L 27/24 - Collagen
• A61L 27/38 - Animal cells
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• C12N 5/09 - Tumour cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Pharmaceutical compositions and pharmaceutical combination preparations. The pharmaceutical compositions and the pharmaceutical combination preparations comprise at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The pharmaceutical compositions or combination preparations may be used in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations may find use for topical application on the skin of a human or animal body.

IPC Classes  ?

• A61K 39/285 - Vaccinia virus or variola virus
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/38 - Albumins
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material

Abstract

The invention relates to a device for assisting with illumination and displaying anatomical boundaries during medical procedures, in particular in the context of an endoscopy, laparoscopy and/or diaphanoscopy, comprising a hollow tube (1) having a proximal end (21) and a distal end (22) and a separate light cable (3), which is guided in a lumen (2) of the hollow tube (1) and is fitted, in its longitudinal extension, with one or more light sources (4) connected in series, the wavelength, frequency and/or intensity of which light sources can be controlled, individually or together, by a control unit (6), wherein the hollow tube (1) can be flexibly shaped and is designed to be light-permeable at least in the region of the light sources (4).

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
• A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
• A61B 1/005 - Flexible endoscopes

Abstract

The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to methods for detecting whether a subject suffers from an autoimmune disease, such as, for example, antiphospholipid syndrome (APS), by detecting antiphospholipid antibodies (aPL) in a sample using a novel target, the lysobisphosphatidic acid (LBPA) bound to the endothelial protein C receptor (EPCR) or an LBPA-binding fragment thereof. Furthermore, the present invention relates to methods for identifying an inhibitor of endothelial protein C receptor (EPCR) function in autoimmune disease, preferably without a side effect on EPCR regulatory function in coagulation, and a method for producing a pharmaceutical composition comprising the steps of identifying a potential inhibitor, and suitably formulating said potential inhibitor into a pharmaceutical composition. Moreover, the present invention relates to said inhibitor as identified or said pharmaceutical composition for use in the prevention and/or treatment of an autoimmune disease, such as, for example, an antiphospholipid syndrome, in a subject. Furthermore, the present invention relates to a method for treating and/or preventing an autoimmune disease, such as, for example, antiphospholipid syndrome, in a subject.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The present invention relates to methods for detecting whether a subject suffers from an autoimmune disease, such as, for example, antiphospholipid syndrome (APS), by detecting antiphospholipid antibodies (aPL) in a sample using a novel target, the lysobisphosphatidic acid (LBPA) bound to the endothelial protein C receptor (EPCR) or an LBPA-binding fragment thereof. Furthermore, the present invention relates to methods for identifying an inhibitor of endothelial protein C receptor (EPCR) function in autoimmune disease, preferably without a side effect on EPCR regulatory function in coagulation, and a method for producing a pharmaceutical composition comprising the steps of identifying a potential inhibitor, and suitably formulating said potential inhibitor into a pharmaceutical composition. Moreover, the present invention relates to said inhibitor as identified or said pharmaceutical composition for use in the prevention and/or treatment of an autoimmune disease, such as, for example, an antiphospholipid syndrome, in a subject. Furthermore, the present invention relates to a method for treating and/or preventing an autoimmune disease, such as, for example, antiphospholipid syndrome, in a subject.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The present invention relates to prooxidative chain-transfer agents for use in the treatment of a malignant tumour disease, or infectious disease. The prooxidative chain-transfer agents are selected from lipophilic thiols, lipophilic trithiocarbonates, lipophilic, aromatic dithioesters, and lipophilic, aromatic thiols. The compounds amplify the prooxidative activity at the target site and are therefore highly efficient and specific for their targets.

IPC Classes  ?

• A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61K 31/275 - NitrilesIsonitriles
• A61P 33/00 - Antiparasitic agents
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a device and a method for determining the severity of sleep apnoea using electroencephalography and electromyography, wherein the device comprises headgear (10; 110) having a head part (12; 112) covering the head of a patient, at least at the locations where the measuring points C3 and C4 of the electroencephalography are situated, and a chin part (14; 114), and wherein the head part (12; 112) has two electrodes (16; 116) for sensing EEG-signals of the electroencephalography at the electroencephalography points C3 and C4, and the chin part (14, 114) has at least one electrode (18; 118) for sensing the EMG-signal of the electromyography in the chin.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/256 - Wearable electrodes, e.g. having straps or bands
• A61B 5/30 - Input circuits therefor
• A61B 5/372 - Analysis of electroencephalograms
• A61B 5/397 - Analysis of electromyograms

Abstract

The present invention relates to a compound comprising a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin-1 (TA-MUC1).

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a device and a method for determining the severity of sleep apnoea using electroencephalography and electromyography, wherein the device comprises headgear (10; 110) having a head part (12; 112) covering the head of a patient, at least at the locations where the measuring points C3 and C4 of the electroencephalography are situated, and a chin part (14; 114), and wherein the head part (12; 112) has two electrodes (16; 116) for sensing EEG-signals of the electroencephalography at the electroencephalography points C3 and C4, and the chin part (14, 114) has at least one electrode (18; 118) for sensing the EMG-signal of the electromyography in the chin.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/256 - Wearable electrodes, e.g. having straps or bands
• A61B 5/30 - Input circuits therefor
• A61B 5/372 - Analysis of electroencephalograms
• A61B 5/397 - Analysis of electromyograms
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61N 2/00 - Magnetotherapy

Abstract

The present invention relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg)-depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

Abstract

The present invention relates to modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. The invention further relates to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening. Finally, the invention also relates to methods for the preparation of a modified NK-92 cell that is specific for a target antigen of a target cell in a subject. The invention also relates to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. The invention further relates to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening. Finally, the invention also relates to methods for the preparation of a modified NK-92 cell that is specific for a target antigen of a target cell in a subject. The invention also relates to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a compounds consisting of one or more peptides comprising the structure in the following order: A-L1-B-L2-C wherein A corresponds to a first amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, B corresponds to a second amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, C corresponds to a third amino acid sequence that is derived from D or B alpha helical region of human or animal IL-4, or D alpha helical region of human or animal IL-13. L1 and L2 correspond to one or more linking amino acids, wherein said compound is capable of stimulating neuronal axon outgrowth.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a finger motion rail (2), and a therapeutic device (1) for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a patient. The rail is characterised in that a means (21) arranged laterally next to the respective finger and/or thumb, for bending a finger base joint (31), is designed as a multiple-joint hinge, which, alongside the connection via a first connection lever (2113), via at least one second (and/or third) connection lever (2203; 2204) and at least one connection joint (2114; 2115), is operatively connected to a mechanism (22) also arranged laterally next to the respective finger and/or thumb, for bending a middle knuckle joint (32) and/or a top knuckle joint (33). The finger motion rail (2) according to the invention or a therapeutic device (1) comprising same is notably more resilient towards the effect of pressing, pulling and torsional forces, in particular in relation to a longitudinal axis (LA) of the finger motion rail (2) and it advantageously allows for a more precise and interference-free execution of an anatomically natural, automated finger movement, which increases the chance of successful therapy and the service life of the device.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The invention relates to a finger motion rail (2), and a therapeutic device (1) for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a patient. The rail is characterised in that a means (21) arranged laterally next to the respective finger and/or thumb, for bending a finger base joint (31), is designed as a multiple-joint hinge, which, alongside the connection via a first connection lever (2113), via at least one second (and/or third) connection lever (2203; 2204) and at least one connection joint (2114; 2115), is operatively connected to a mechanism (22) also arranged laterally next to the respective finger and/or thumb, for bending a middle knuckle joint (32) and/or a top knuckle joint (33). The finger motion rail (2) according to the invention or a therapeutic device (1) comprising same is notably more resilient towards the effect of pressing, pulling and torsional forces, in particular in relation to a longitudinal axis (LA) of the finger motion rail (2) and it advantageously allows for a more precise and interference-free execution of an anatomically natural, automated finger movement, which increases the chance of successful therapy and the service life of the device.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The invention relates to a length-adjustment device (3) for a finger motion rail (2) of a therapeutic device (1) for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a hand, a finger motion rail (2) comprising a length-adjustment device (3) of this type, and a corresponding therapeutic device (1) comprising at least one finger motion rail (2) of this type. The invention also relates to a method for adjusting the length of a finger motion rail (2) on a therapeutic device (1) of this type. The length-adjustment device (3) according to the invention or the length-adjustment method according to the invention advantageously allows for a finger motion rail (2) to be automatically shifted along the adjustment rail (30) using the drive (10) already provided on a therapeutic device (1) for the finger motion rail (2), and for same to be fixed on the adjustment rail (30) and therefore on the therapeutic device (1) in a desired position according to the finger length or hand size/length of the user, in order to then be able to carry out a continuous, passive and/or actively assisted movement of a finger and/or of a thumb of a hand in a stable position. Time-consuming manual adjustment is thereby advantageously avoided.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The invention relates to a method for classifying a polysomnography recording into defined sleep stages, the method comprising essentially the following steps: dividing the sleep of a person into different identifiable sleep stages; capturing a plurality of pieces of information regarding bodily functions over a specified time period in the form of data, the data comprising at least one data set of a data type of a first nature, by means of which data set the sleep stages can be identified; splitting the captured data into time-dependent data blocks; manually selecting a limited number of training data blocks from the data blocks and associating them with a sleep stage; evaluating the data set of the first nature of each training data block by means of a data-processing method; creating training objects, each training object comprising the evaluated data sets of the first nature of a training data block and the association of the training data block with a sleep stage; transmitting the training objects to a support vector machine for creating a classification; transmitting at least some of the data blocks that were not selected as training data blocks to the support vector machine.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention relates to a method for classifying a polysomnography recording into defined sleep stages, the method comprising essentially the following steps: dividing the sleep of a person into different identifiable sleep stages; capturing a plurality of pieces of information regarding bodily functions over a specified time period in the form of data, the data comprising at least one data set of a data type of a first nature, by means of which data set the sleep stages can be identified; splitting the captured data into time-dependent data blocks; manually selecting a limited number of training data blocks from the data blocks and associating them with a sleep stage; evaluating the data set of the first nature of each training data block by means of a data-processing method; creating training objects, each training object comprising the evaluated data sets of the first nature of a training data block and the association of the training data block with a sleep stage; transmitting the training objects to a support vector machine for creating a classification; transmitting at least some of the data blocks that were not selected as training data blocks to the support vector machine.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/048 - Detecting the frequency distribution of signals
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

A catheter for insertion into a vessel (6) is designed at its free end (2) such that, in a first state, it is cylindrical and, in a second state, it has a conical shape, the largest diameter being associated with the peripheral end (2). The aim of the invention is that of providing a catheter of the type mentioned at the outset which avoids thrombus material trapped in a stent from being removed when a stent is retracted.

IPC Classes  ?

• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
• A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques

Abstract

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to pharmaceutical compositions, comprising at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The invention further relates pharmaceutical combination preparations comprising these components and the use of such pharmaceutical compositions or combination preparations for use in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations of the invention are in particular useful for topical application on the skin of a human or animal body.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to pharmaceutical compositions, comprising at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The invention further relates pharmaceutical combination preparations comprising these components and the use of such pharmaceutical compositions or combination preparations for use in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations of the invention are in particular useful for topical application on the skin of a human or animal body.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 37/04 - Immunostimulants

Abstract

3)22333233223. 3. The invention further relates to pharmaceutical compositions comprising one or more of said flavagline derivatives and the use in methods for inhibition of KRAS activation.

IPC Classes  ?

• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a skinfold chamber system comprising a U-shaped folding frame having an outer U-shaped frame part and an inner U-shaped frame part. The two frame parts are coupled to one another at the open ends of the U legs thereof by means of an articulated connection in such a way that the inner frame part can be folded against the outer frame part such that, in the folded-in state, the inner frame part can be or is positioned within the U opening of the outer frame part and, in the folded-out state, the inner frame part and the outer frame part lie mirror-symmetrical to one another and surround an opening. The outer frame part and the inner frame part each have an L-shaped profile in cross-section, and therefore each frame part has a frame wall which is horizontal with respect to the plane of the folding frame and extends in a U shape and a frame wall which is vertical with respect to the plane of the folding frame and extends in a U shape. The two frame parts are oriented relative to one another in such a way that, in the closed position of the folding frame, the vertical frame walls of the two frame parts run approximately parallel to one another and the horizontal frame walls of the two frame parts are oriented substantially in the same plane and in opposite directions with respect to one another.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV.

IPC Classes  ?

• C12N 7/04 - Inactivation or attenuationProducing viral sub-units

Abstract

The present invention relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg)-depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg)-depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

Abstract

The present invention relates to a compound comprising - a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), - a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin- (TA-MUC1).

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a compound comprising - a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), - a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin- (TA-MUC1).

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a compound consisting of one or more peptides comprising the structure in the following order: A - L1 - B - L2 - C wherein A corresponds to a first amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, B corresponds to a second amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, C corresponds to a third amino acid sequence that is derived from D or B alpha helical region of human or animal IL-4, or D alpha helical region of human or animal IL-13. L1 and L2 correspond to one or more linking amino acids, wherein said compound is capable of stimulating neuronal axon outgrowth.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/00 - Drugs for disorders of the nervous system
• C07K 14/54 - Interleukins [IL]

Abstract

The present invention relates to a compound consisting of one or more peptides comprising the structure in the following order: A - L1 - B - L2 - C wherein A corresponds to a first amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, B corresponds to a second amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, C corresponds to a third amino acid sequence that is derived from D or B alpha helical region of human or animal IL-4, or D alpha helical region of human or animal IL-13. L1 and L2 correspond to one or more linking amino acids, wherein said compound is capable of stimulating neuronal axon outgrowth.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/54 - Interleukins [IL]

Abstract

The present invention relates to vaccines comprising a polypeptide or protein selected from the group consisting of Leishmania major p54, Q4Q8Z6, Q4Q6L9, Q4QHT2, E9AE98, or an immunologically effective fragment thereof, for use in the prevention or treatment of leishmaniasis. The invention further relates to a pharmaceutical composition comprising such a vaccine.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 39/008 - Leishmania antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A catheter for insertion into a vessel (6) has a free end (2) designed such that in a first state the catheter is cylindrical and in a second state it is conical, the peripheral end (2) having the largest diameter. The aim of the invention is to devise a catheter of the above-mentioned type which avoids thrombic material that is trapped in a stent from being inadvertently removed when the stent is retracted.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes
• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for

Abstract

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/433 - Thiadiazoles
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1α) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1α) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PCG-1α or an upstream regulator of Treg-resistant T-cells HNF4A, Hdac, RORA, ESRRA, LPIN1 can be used in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/02 - Inorganic compounds
• G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard

Abstract

The present invention relates to a device for ultrasonic-accelerated hematoma lysis or thrombolysis of intracerebral or intraventricular hemorrhages or hematomas, comprising a body (20) which accommodates a number of separated compartments or lumens consisting of a flushing catheter (1) for flushing fluid and/or pharmaceutically active substances into the intracerebral or intraventricular hemorrhages or hematomas, a drainage catheter (2) for draining fluid from the intracerebral or intraventricular hemorrhages or hematomas, an ultrasonic probe duct (3), and a pressure sensor duct (5), wherein the compartments or lumens are arranged in proximity to each other and wherein in longitudinal extension at least upper-part sections of the compartments or lumens are isolated by walls, wherein the lumen of the pressure sensor duct (5) integrates a pressure sensor (6), and wherein in the lumen of ultrasonic probe duct (3) an endosonographic probe (4) or a stiletto (13) is interchangeably guided.

IPC Classes  ?

• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61N 7/00 - Ultrasound therapy
• A61N 7/02 - Localised ultrasound hyperthermia
• A61M 25/00 - CathetersHollow probes
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present invention relates to 3-(5-fluoroindolyl)-4-arylmaleimide compounds and pharmaceutical compositions containing them. The compounds of the present invention are protein kinases (GSK-3beta, VEGFR-2 and FLT-3) with antineoplastic activity. They can therefore be used for the treatment or prevention of tumors, in particular solid tumors.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61P 35/00 - Antineoplastic agents
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

A monitoring assembly comprises probes (1, 4) for inserting into a body, the first probe (1) being coupled to at least one light source (8) or acoustic source in order to generate a stimulation signal and the second probe (4) being arranged in order to detect a response signal of a target organ. The stimulation signal is suitable for differentiating between neuronal tissue and non-neuronal tissue, whereas the response signal is detected as an EMG signal or pressure signal. The two probes are connected to a monitoring computer (15) via control- (9, 13) and evaluation devices (10, 14).

IPC Classes  ?

• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61N 5/06 - Radiation therapy using light
• A61N 7/00 - Ultrasound therapy

Abstract

The present invention relates to a method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), referred to as Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1- alpha, PPARGC1A (PGC-1 a) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. Furthermore, the invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1 A (PGC-lalpha) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PCG-lalpha or an upstream regulator of Treg- resistant T-cells HNF4A, Hdac, RORA, ESRRA, LPIN1 can be used in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to a method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), referred to as Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1- alpha, PPARGC1A (PGC-1 a) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. Furthermore, the invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1 A (PGC-lalpha) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PCG-lalpha or an upstream regulator of Treg- resistant T-cells HNF4A, Hdac, RORA, ESRRA, LPIN1 can be used in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The present invention relates to a novel tracheal cannula (10), which allows patients to speak who receive artificial respiration with compressed-air. The tracheal cannula according to the invention makes this possible without the risk that saliva or stomach content is aspirated and without the occurrence of a loss of pressure during the respiration. This is achieved by an embodiment of the cannula having a separated speaking conduit (12) and respiration conduit (11). Furthermore, the invention relates to a speaking respiration system that can be connected to the tracheal cannula of the present invention, and that when used in a patient monitors and controls the respiration of the patient, and simulates an artificial exhalation that enables the tracheostomized patient to speak.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61M 16/16 - Devices to humidify the respiration air
• A61M 16/20 - Valves specially adapted to medical respiratory devices
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes

Abstract

The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to methods of identifying the risk of a subject developing lupus nephritis (LN) by measuring the CSF-1 level in a sample obtained from the subject. For a subject having systemic lupus erythematosus (SLE) or in remission of LN, tracking the CSF-1 levels of the subject over time can permit one to predict the likelihood of the subject developing LN or LN flares. For a subject having LN and receiving treatment for LN, the treatment progress can be monitored by tracking the CSF-1 levels of the subject over time. Furthermore, CSF-1 can be a therapeutic target for treating LN.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 35/00 - Antineoplastic agents
• A61K 35/26 - LymphLymph nodesThymusSpleenSplenocytesThymocytes

Abstract

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids